New hope for hard-to-treat colorectal cancer: drug combo targets resistant tumors

NCT ID NCT06558773

First seen Feb 20, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study tests whether adding a GSL synthetase inhibitor (eliglustat) to standard treatments can shrink tumors or slow cancer growth in people with advanced colorectal cancer that has not responded to at least two prior therapies. About 120 adults with a specific tumor type (pMMR/MSS) will be randomly assigned to one of three treatment groups. The goal is to find a more effective way to control this difficult-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China

    RECRUITING

    Beijing, Biotherapeutic Department of Chinsese PLA Gereral Hospital, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.